{"filings":[{"id":2106196,"accession_number":"0001193125-26-338068","cik":1824893,"company_name":"Surrozen, Inc./DE","ticker":"SRZN","form_type":"8-K","filed_at":"2026-08-06T20:15:55+00:00","items":["2.02","9.01"],"status":"ready","headline":"Surrozen reports Q2 2026 results; IND for SZN-8141 planned by Q3 end; PTAB denies Merck petition","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Planned IND submission for SZN-8141 in DME by end of Q3 2026; DUET Phase 1b/2a to start by year-end 2026 with initial data in H2 2027.","PTAB denied Merck's post-grant review petition challenging Surrozen's U.S. Patent No. 12,297,278, reinforcing IP position.","Boehringer Ingelheim milestone triggered $5.0M collaboration revenue in Q2 2026 (vs $0 in Q2 2025).","Cash and cash equivalents $102.0M as of June 30, 2026, down from $106.9M as of March 31, 2026.","Net income $50.2M (including $59.6M non-cash gains) vs $39.7M (including $47.6M non-cash gains) in Q2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":307210407.48949176,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":442796,"accession_number":"0001193125-26-224037","cik":1824893,"company_name":"Surrozen, Inc./DE","ticker":"SRZN","form_type":"8-K","filed_at":"2026-05-14T20:13:22+00:00","items":["5.07"],"status":"ready","headline":"Surrozen stockholders elect two Class II directors, ratify EY auditor, approve say-on-pay on annual basis","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Mace Rothenberg, M.D. (5,982,651 for, 1,107,751 withheld) and David J. Woodhouse (7,087,293 for, 3,109 withheld) as Class II directors.","Ratified Ernst & Young LLP as independent auditor for 2026: 7,744,358 for, 284 against, 27 abstain.","Advisory vote on executive compensation approved: 6,312,815 for, 776,738 against, 849 abstain, 654,267 broker non-votes.","Stockholders preferred annual say-on-pay frequency (7,068,763 votes for 1 year); board adopted annual advisory vote going forward.","Total shares represented at meeting: 7,744,669 of 11,486,707 entitled; no proposals opposed by management."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":307210407.48949176,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95866,"accession_number":"0001193125-26-208999","cik":1824893,"company_name":"Surrozen, Inc./DE","ticker":"SRZN","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Surrozen Q1 2026 net loss $127.5M; cash $106.9M; on track for SZN-8141 IND in H2 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $127.5M ($11.65/sh) vs $27.0M ($7.43/sh) in Q1 2025, driven by non-cash fair value changes on warrants and tranche liability.","Cash and equivalents $106.9M as of Mar 31, 2026, up from $89.2M at Dec 31, 2025.","Received $5M milestone payment from Boehringer Ingelheim in April 2026 for SZN-413 GLP toxicology study progress.","On track to submit IND for SZN-8141 for retinal diseases in H2 2026; preclinical data presented at ARVO.","R&D expenses $9.3M (up $2.7M YoY) due to ophthalmology program costs; G&A $6.1M (up $2.1M)."],"consensus_eps_estimate":null,"consensus_eps_actual":-11.65,"consensus_revenue_estimate":null,"consensus_revenue_actual":5000000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":307210407.48949176,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109251,"accession_number":"0001193125-26-119757","cik":1824893,"company_name":"Surrozen, Inc./DE","ticker":"SRZN","form_type":"8-K","filed_at":"2026-03-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Surrozen reports FY2025 net loss $242M; cash $89.2M; expects IND for SZN-8141 in H2 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $89.2M at Dec 31, 2025, up from $34.6M year-end 2024; additional $30.2M raised in early 2026 via ATM and warrant exercises.","Full year net loss $242.0M ($32.37 per share) vs $63.6M in 2024, driven by non-cash PIPE-related charges (tranche liability, warrant revaluation).","No collaboration revenue in 2025 vs $10M in 2024; research service revenue from terminated TCGFB deal was $3.5M.","Received $5M milestone from Boehringer Ingelheim for SZN-413 after successful IND-enabling GLP tox study.","On track to submit IND for SZN-8141 (retinal disease) to FDA in H2 2026; will present at ARVO in May 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":307210407.48949176,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109250,"accession_number":"0001193125-26-031798","cik":1824893,"company_name":"Surrozen, Inc./DE","ticker":"SRZN","form_type":"8-K","filed_at":"2026-01-30T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Shao-Lee Lin resigns from Surrozen board effective immediately","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Shao-Lee Lin, M.D., Ph.D., resigned from the Board on January 26, 2026, effective immediately.","Resignation was not due to any disagreement with the Company's operations, policies or practices.","Surrozen thanks Dr. Lin for her service and dedication to the Company's mission."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":307210407.48949176,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125744,"accession_number":"0001193125-25-272363","cik":1824893,"company_name":"Surrozen, Inc./DE","ticker":"SRZN","form_type":"8-K","filed_at":"2025-11-07T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Surrozen Q3 net loss $71.6M, appoints new CFO","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $71.6M ($8.36/diluted share) vs $1.4M ($0.44) YoY; driven by $40.7M non-cash tranche liability loss and $20.9M other expense.","Revenue fell to $1.0M (all from related party) from $10.0M in Q3 2024, due to absence of Boehringer Ingelheim milestone payment.","Cash $81.3M at Sep 30, 2025 (down from $90.4M at Jun 30); R&D $7.8M vs $5.2M, G&A $4.1M vs $3.6M YoY.","Andrew Maleki appointed CFO effective Nov 12, 2025; Charles Williams continues as COO and Secretary.","Company on track to submit IND for SZN-8141 in 2026; ophthalmology pipeline remains focus."],"consensus_eps_estimate":null,"consensus_eps_actual":-8.49,"consensus_revenue_estimate":null,"consensus_revenue_actual":2949000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":307210407.48949176,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125743,"accession_number":"0001193125-25-242518","cik":1824893,"company_name":"Surrozen, Inc./DE","ticker":"SRZN","form_type":"8-K","filed_at":"2025-10-17T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Surrozen's collaboration agreement terminated by TCGFB for convenience, effective Nov 13","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["TCGFB terminated Collaboration Agreement for convenience; no termination penalties incurred by either party.","Agreement provided Surrozen up to $6.0M in payments plus warrant for 3.4M TCGFB shares at $0.0001/share.","Collaboration was for antibody discovery services; TCGFB owned all TGF-β product IP.","TCGFB is affiliated with The Column Group, a >5% holder of Surrozen stock; board member Kutzkey is TCG Managing Partner."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":307210407.48949176,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142464,"accession_number":"0000950170-25-112253","cik":1824893,"company_name":"Surrozen, Inc./DE","ticker":"SRZN","form_type":"8-K","filed_at":"2025-08-29T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Surrozen enters ATM equity offering agreement for up to $50M with TD Cowen","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sales Agreement with TD Securities (USA) LLC to sell up to $50M of common stock at-the-market or in negotiated transactions.","TD Cowen will receive a 3% commission on gross proceeds from shares sold.","Offering is made under existing S-3 registration statement and prospectus supplement dated August 29, 2025.","Surrozen is not obligated to sell any shares; agreement may be terminated by either party on written notice.","Cooley LLP issued a legal opinion on the validity of the shares, filed as Exhibit 5.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":307210407.48949176,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142463,"accession_number":"0000950170-25-105839","cik":1824893,"company_name":"Surrozen, Inc./DE","ticker":"SRZN","form_type":"8-K","filed_at":"2025-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Surrozen Q2 2025 net income $39.7M on non-cash gains; cash $90.4M, appoints new clinical VP","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income of $39.7M ($2.55/diluted share) versus net loss of $25.3M in Q2 2024; driven by non-cash gains on tranche liability and warrant revaluation.","Cash and cash equivalents $90.4M at June 30, 2025, down from $101.6M at March 31, 2025.","Appointed Daniel Chao, M.D., Ph.D., as VP and Head of Clinical Development; also formed Clinical Advisory Board with four retinal specialists.","Granted U.S. Patent No. 12,297,278 covering SWAP multi-specific Wnt surrogate technology; IND submission for SZN-8141 targeted for 2026.","R&D expenses $6.0M (up from $5.3M) and G&A $4.0M (up from $3.7M); research service revenue from related party $1.0M."],"consensus_eps_estimate":null,"consensus_eps_actual":0.85,"consensus_revenue_estimate":null,"consensus_revenue_actual":1966000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":307210407.48949176,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160508,"accession_number":"0000950170-25-072696","cik":1824893,"company_name":"Surrozen, Inc./DE","ticker":"SRZN","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Surrozen stockholders elect three Class I directors and ratify Ernst & Young as auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Anna Berkenblit, M.D. elected with 1,351,951 for, 503,791 withheld, 453,045 broker non-votes.","Eric Bjerkholt elected with 1,787,859 for, 67,883 withheld, 453,045 broker non-votes.","Tim Kutzkey, Ph.D. elected with 1,851,021 for, 4,721 withheld, 453,045 broker non-votes.","Ratification of Ernst & Young as independent auditor for FY2025 passed with 2,307,951 for, 0 against, 836 abstain.","No other matters were submitted to a vote; 2,308,787 shares represented (70.4% of eligible)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":307210407.48949176,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160507,"accession_number":"0000950170-25-068011","cik":1824893,"company_name":"Surrozen, Inc./DE","ticker":"SRZN","form_type":"8-K","filed_at":"2025-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Surrozen Q1 net loss $27M, cash $101.6M; discontinues SZN-043, pivots to ophthalmology","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $27.0M ($7.43 per share) vs $8.8M ($4.24 per share) in Q1 2024; R&D expenses $6.6M.","Cash increased to $101.6M from $34.6M at year-end 2024, boosted by $76.4M from first tranche of $175M private placement.","Discontinued SZN-043 for severe alcohol-associated hepatitis due to insufficient Phase 1b benefit; shifted focus to ophthalmology.","Expects to file IND for lead candidate SZN-8141 in 2026; FDA clearance triggers $98.6M tranche to fund operations.","Research service revenue $1.0M from TCGFB collaboration; other income $38.0M from non-cash warrant valuation changes."],"consensus_eps_estimate":-1.8207,"consensus_eps_actual":-7.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":983000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":307210407.48949176,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178757,"accession_number":"0000950170-25-047702","cik":1824893,"company_name":"Surrozen, Inc./DE","ticker":"SRZN","form_type":"8-K","filed_at":"2025-03-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Surrozen reports FY2024 net loss of $63.6M; secures $76.4M financing for ophthalmology pipeline","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $63.6M for 2024 vs $43.0M in 2023; Q4 net loss $28.0M.","Cash $34.6M at 12/31/2024; received $76.4M gross proceeds from March 2025 financing.","Collaboration revenue $10.0M for 2024, driven by Boehringer milestone; zero in 2023.","R&D expenses $21.1M, down from $27.2M in 2023 due to restructuring and program discontinuation.","Company prioritizing ophthalmology programs; Boehringer advancing SZN-413 toward clinical testing."],"consensus_eps_estimate":-1.8207,"consensus_eps_actual":-7.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":983000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":307210407.48949176,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178756,"accession_number":"0000950170-25-046769","cik":1824893,"company_name":"Surrozen, Inc./DE","ticker":"SRZN","form_type":"8-K","filed_at":"2025-03-28T23:59:59+00:00","items":["1.01","3.02","5.02","9.01"],"status":"ready","headline":"Surrozen raises ~$76.4M in first tranche private placement; appoints Tim Kutzkey to Board","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First tranche closed March 26, 2025; gross proceeds ~$76.4M from 6,586,415 Units at $11.60 each.","Each Unit includes one share (or pre-funded warrant) and one-half Series E Common Warrant ($11.54 exercise, 5-year term).","Second tranche of up to 8,499,821 Units (~$98.6M) conditioned on FDA IND clearance for SZN-8141 by Oct 31, 2026.","Series C and D warrants cancelled; Series A and B exercise prices reduced to $11.54 (management: $12.45).","Dr. Tim Kutzkey (The Column Group) appointed as Class I director; initial option grant for 2,666 shares at $10.66."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":307210407.48949176,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178755,"accession_number":"0001193125-25-061361","cik":1824893,"company_name":"Surrozen, Inc./DE","ticker":"SRZN","form_type":"8-K","filed_at":"2025-03-24T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Surrozen secures $175M PIPE for ophthalmology Wnt mimetics, drops liver program","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Oversubscribed $175M private placement (two tranches: $70M initial, $105M contingent on FDA clearance) led by Venrock Healthcare Capital Partners.","Prioritizes ophthalmology pipeline: lead candidates SZN-8141 (Fzd4/VEGF) and SZN-8143 (Fzd4/VEGF/IL-6) for retinopathies.","Discontinues SZN-043 in severe alcohol-associated hepatitis due to insufficient clinical benefit signal relative to development path.","Tim Kutzkey, Ph.D. joins Board of Directors; Series A/B warrant exercise prices reduced, Series C/D warrants cancelled.","Funds multiple ophthalmology programs through Phase 1 safety, tolerability and efficacy studies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":307210407.48949176,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195431,"accession_number":"0000950170-24-121856","cik":1824893,"company_name":"Surrozen, Inc./DE","ticker":"SRZN","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Surrozen reports Q3 net loss of $1.4M (vs $10.4M YoY); gets $10M BI milestone for SZN-413","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss narrowed to $1.4M from $10.4M in Q3 2023; collaboration revenue $10.0M (BI milestone).","Cash $31.0M at Sep 30, 2024; plus $10M milestone received Oct 2024 from Boehringer Ingelheim.","Phase 1b SZN-043 in severe alcohol-associated hepatitis: cohort 1 completed; no SAEs, reduced bilirubin/MELD; PoC data expected H1 2025.","Nominated wholly-owned preclinical ophthalmology candidates SZN-8141/8143/113 targeting Fzd4; SZN-413 advancing with BI.","New TCGFB research collaboration for TGF-β antibodies in IPF; up to $6M plus equity warrant of 3.38M shares."],"consensus_eps_estimate":null,"consensus_eps_actual":-12.57,"consensus_revenue_estimate":null,"consensus_revenue_actual":10000000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":307210407.48949176,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195430,"accession_number":"0000950170-24-111493","cik":1824893,"company_name":"Surrozen, Inc./DE","ticker":"SRZN","form_type":"8-K","filed_at":"2024-10-02T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Surrozen extends HQ lease through April 2029 with escalating rent, $400K early termination option","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lease term extended 48 months to April 2029; annual base rent starts at $2.3M, rises to $2.6M.","Early termination option (April 2026) requires $400K fee by Dec 31, 2025; notice by Sep 30, 2025.","Extension option reduced from two 5-year to one 4-year option following extended term.","Rent abatement for Jan-Mar 2026 applies if early termination option not exercised.","Amendment updates assignment, net worth, and financial reporting provisions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":307210407.48949176,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211691,"accession_number":"0000950170-24-095414","cik":1824893,"company_name":"Surrozen, Inc./DE","ticker":"SRZN","form_type":"8-K","filed_at":"2024-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Surrozen Q2 net loss widens to $25.3M on $20.4M warrant loss; cash at $37.8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and cash equivalents $37.8M as of June 30, 2024, up from $27.3M at March 31, 2024.","Net loss $25.3M vs $9.4M in Q2 2023; includes $20.4M loss on issuance of pre-funded warrants and warrants.","R&D expenses decreased to $5.3M from $6.9M YoY, reflecting 2023 restructuring.","Phase 1b trial of SZN-043 for severe alcoholic hepatitis ongoing; proof-of-concept data expected H1 2025.","Boehringer Ingelheim partnership for SZN-413 may trigger $10M milestone if lead candidate nominated in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-13.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":307210407.48949176,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211690,"accession_number":"0000950170-24-079690","cik":1824893,"company_name":"Surrozen, Inc./DE","ticker":"SRZN","form_type":"8-K","filed_at":"2024-07-01T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Surrozen director Tim Kutzkey resigns from board and committees effective June 30","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Tim Kutzkey, Ph.D. resigned as director and from all board committees on June 30, 2024.","Resignation is not due to any disagreement with the company on operations, policies, or practices.","No replacement has been announced as of the filing date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":307210407.48949176,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230422,"accession_number":"0000950170-24-070741","cik":1824893,"company_name":"Surrozen, Inc./DE","ticker":"SRZN","form_type":"8-K","filed_at":"2024-06-07T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Surrozen reports 2024 annual meeting vote results: directors elected, auditor ratified","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Three Class III directors elected: Christopher Y. Chai, Mary Haak-Frendscho, and Craig Parker.","Christopher Y. Chai: 1,267,311 for, 147,380 withheld; broker non-votes 393,588.","Mary Haak-Frendscho: 1,410,102 for, 4,589 withheld; broker non-votes 393,588.","Craig Parker: 1,409,464 for, 5,227 withheld; broker non-votes 393,588.","Ratification of Ernst & Young as auditor for FY2024: 1,803,744 for, 416 against, 4,119 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":307210407.48949176,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230421,"accession_number":"0000950170-24-055667","cik":1824893,"company_name":"Surrozen, Inc./DE","ticker":"SRZN","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Surrozen Q1 net loss $8.8M; cash $27.3M; SZN-043 Phase 1b enrollment starts Q2 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $27.3M at Mar 31; proforma $43.2M after April financing. Net loss $8.8M vs $14.3M YoY.","R&D expense $5.2M (down 36% YoY); G&A $3.9M (down 26% YoY) reflecting 2023 restructuring.","SZN-043 Phase 1a completed; Phase 1b enrollment to begin Q2 2024; proof-of-concept data expected H1 2025.","Potential $10M milestone from Boehringer Ingelheim if lead Fzd-4 Wnt agonist candidate nominated in 2024.","Preclinical data at ARVO on Wnt mimetic for corneal dystrophies; publication on pulmonary fibrosis in Respiratory Research."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":307210407.48949176,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230420,"accession_number":"0000950170-24-040337","cik":1824893,"company_name":"Surrozen, Inc./DE","ticker":"SRZN","form_type":"8-K","filed_at":"2024-04-02T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Surrozen raises $17.5M in private placement with milestone-triggered warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issues 1,089,033 shares at $15.50 and pre-funded warrants for 40,000 shares at $15.4999.","Management purchases 2,948 shares at $16.96; total gross proceeds ~$17.5M.","Series A warrants: 1,129,033 shares at $15.50, exercisable for 5 years.","Series B warrants: 1,228,071 shares at $14.25; exercisable after 15-patient enrollment milestone in SZN-043 trial.","Series C/D warrants: each up to 4,375,000 shares at $16.00, exercisable after Phase 1b data or ≥50 patient enrollment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":307210407.48949176,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230419,"accession_number":"0000950170-24-038902","cik":1824893,"company_name":"Surrozen, Inc./DE","ticker":"SRZN","form_type":"8-K","filed_at":"2024-04-01T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Surrozen reports Phase 1a SZN-043 data: safe, target engagement, liver function effects; Phase 1b starts","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 1a enrolled 48 subjects (40 healthy, 8 cirrhotic); doses 0.5-3 mg/kg IV; no serious adverse events.","Demonstrated target engagement via transient ALP increases and Wnt pathway activation by methacetin breath test.","In cirrhotic patients, dose-dependent pharmacodynamic effect and improvement in liver function via HepQuant test observed.","Initiating Phase 1b proof-of-concept trial in severe alcohol-associated hepatitis; data expected first half 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":307210407.48949176,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248819,"accession_number":"0000950170-24-011936","cik":1824893,"company_name":"Surrozen, Inc./DE","ticker":"SRZN","form_type":"8-K","filed_at":"2024-02-07T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Surrozen appoints CFO Charles Williams as COO, retains CFO role; salary increased to $465,000","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Charles Williams appointed Chief Operating Officer effective Feb 1, 2024, while continuing as CFO.","Annual base salary raised to $465,000 as part of annual compensation review.","No arrangements or family relationships exist per Item 404(a) of Reg S-K.","Williams has held CFO role since November 2020; standard indemnification agreement in place."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":307210407.48949176,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248818,"accession_number":"0000950170-24-005198","cik":1824893,"company_name":"Surrozen, Inc./DE","ticker":"SRZN","form_type":"8-K","filed_at":"2024-01-18T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Surrozen discontinues SZN-1326; SZN-043 Phase 1a complete, data due Q1 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["SZN-043 Phase 1a enrollment in chronic liver disease and healthy volunteers complete; safety/pharmacodynamic data expected Q1 2024.","Phase 1b for alcohol-associated hepatitis to initiate soon; proof-of-concept data possible in H2 2024.","SZN-1326 development in IBD discontinued due to asymptomatic grade 3 ALT/AST elevations at high doses and strategic factors.","No serious adverse events in SZN-1326 trial; transaminase elevations resolved spontaneously in all subjects."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":307210407.48949176,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":266324,"accession_number":"0000950170-23-070103","cik":1824893,"company_name":"Surrozen, Inc./DE","ticker":"SRZN","form_type":"8-K","filed_at":"2023-12-13T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Surrozen announces 1-for-15 reverse stock split effective December 13, 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Effective Dec 13, 2023, Surrozen effected a 1-for-15 reverse stock split of its common stock.","Stockholders approved the reverse split at a special meeting on Dec 7, 2023; board set ratio at 1:15.","Common stock begins trading on split-adjusted basis Dec 14, 2023 under same ticker SRZN; new CUSIP 86889P208.","Warrants adjusted: every 15 pre-split warrants now represent 1 share; exercise price increased to $172.50 from $11.50.","No fractional shares issued; cash payments in lieu of fractional shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":307210407.48949176,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":266323,"accession_number":"0000950170-23-069405","cik":1824893,"company_name":"Surrozen, Inc./DE","ticker":"SRZN","form_type":"8-K","filed_at":"2023-12-11T23:59:59+00:00","items":["5.07","8.01"],"status":"ready","headline":"Surrozen stockholders approve 1-for-15 reverse stock split, effective Dec 13, 2023","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Special meeting Dec 7: 16.2M shares for, 784K against, 0.5K abstain on reverse-split amendment.","Board set ratio at 1:15; effective Dec 13; every 15 shares convert to 1 share, no par value change.","Common stock trades split-adjusted on Nasdaq under SRZN starting Dec 14; new CUSIP 86889P208.","Warrants adjusted: exercise price increases to $172.50 from $11.50; shares per warrant reduced proportionately.","No fractional shares issued; cash paid in lieu of fractional shares; par value remains $0.0001."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":307210407.48949176,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":266322,"accession_number":"0000950170-23-061101","cik":1824893,"company_name":"Surrozen, Inc./DE","ticker":"SRZN","form_type":"8-K","filed_at":"2023-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Surrozen Q3 net loss $10.4M; cash $43.4M; Phase 1a data expected Q1 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $10.4M vs $13.4M prior year; R&D expenses down to $6.1M from $8.6M.","Cash and securities $43.4M (Sept 30, 2023), down from $53.4M (June 30, 2023); runway into 2025.","Phase 1a data for SZN-043 and SZN-1326 expected Q1 2024; Phase 1b studies to initiate in 2024.","Two new USPTO patents granted (Nos. 11/746,150 and 11/773,171) for SZN-1326 and SWAP technology.","Boehringer Ingelheim partnership: potential $10M milestone in 2024 upon candidate nomination."],"consensus_eps_estimate":null,"consensus_eps_actual":1.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":307210407.48949176,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":266321,"accession_number":"0000950170-23-053312","cik":1824893,"company_name":"Surrozen, Inc./DE","ticker":"SRZN","form_type":"8-K","filed_at":"2023-10-13T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Surrozen amends bylaws to reduce stockholder quorum to one-third voting power","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board amended and restated Bylaws effective October 10, 2023.","Quorum reduced from majority to at least one-third of voting power of outstanding shares.","Change applies to all meetings and separate class/ series votes unless law or charter requires otherwise.","Text of amended Bylaws filed as Exhibit 3.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":307210407.48949176,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283580,"accession_number":"0000950170-23-040611","cik":1824893,"company_name":"Surrozen, Inc./DE","ticker":"SRZN","form_type":"8-K","filed_at":"2023-08-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Surrozen Q2 net loss $9.4M; cash runway extended into 2025 on prioritization","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $9.4M improved from $13.9M YoY; cash and securities $53.4M (down from $61.7M in Q1).","R&D expenses fell to $6.9M from $9.6M YoY; G&A expenses to $3.3M from $4.5M YoY.","SZN-043 Phase 1a enrollment continues; safety data expected by end of 2023; Phase 1b in alcoholic hepatitis planned for 2024.","SZN-1326 Phase 1a enrollment continues; Phase 1b in ulcerative colitis planned for 2024, proof-of-concept data expected H2 2024.","Boehringer Ingelheim partnership may trigger $10M milestone in 2024 upon Fzd-4 candidate nomination."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.79,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":307210407.48949176,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283579,"accession_number":"0000950170-23-033527","cik":1824893,"company_name":"Surrozen, Inc./DE","ticker":"SRZN","form_type":"8-K","filed_at":"2023-07-19T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Surrozen CSO Wen-Chen Yeh departs in restructuring; receives $337K severance, moves to advisory board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CSO Wen-Chen Yeh to step down on July 31, 2023, as part of a planned restructuring and reduction-in-force.","Dr. Yeh will transition to the Scientific Advisory Board; existing equity awards continue vesting during advisory service.","Separation agreement provides $337,365 lump-sum severance (9 months salary) and COBRA premiums paid until April 30, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":307210407.48949176,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283578,"accession_number":"0000950170-23-031664","cik":1824893,"company_name":"Surrozen, Inc./DE","ticker":"SRZN","form_type":"8-K","filed_at":"2023-07-05T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Surrozen gets Nasdaq extension to Jan 2, 2024 to meet $1 bid price","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice of additional 180-day period to regain minimum $1.00 bid price compliance.","Initial compliance period ended July 3, 2023; stock had not regained compliance.","To cure, Company may effect a reverse stock split before January 2, 2024.","Closing bid must be at least $1.00 for 10 consecutive business days during extension.","Failure to comply by Jan 2, 2024 may result in delisting; Company may appeal."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":307210407.48949176,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":303093,"accession_number":"0000950170-23-023389","cik":1824893,"company_name":"Surrozen, Inc./DE","ticker":"SRZN","form_type":"8-K","filed_at":"2023-05-22T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Surrozen stockholders re-elect three directors and ratify EY as auditor for 2023","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual meeting held May 18, 2023; 18,247,744 of 30,079,441 shares represented.","Directors Shao-Lee Lin, Mace Rothenberg, and David Woodhouse re-elected to three-year terms.","Each director received over 10.9M votes for; broker non-votes were 3,087,115.","Ratification of Ernst & Young as independent auditor for FY2023: 18,240,296 for, 499,008 against, 4,440 abstain.","No other matters submitted to shareholder vote."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":307210407.48949176,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":303092,"accession_number":"0000950170-23-020519","cik":1824893,"company_name":"Surrozen, Inc./DE","ticker":"SRZN","form_type":"8-K","filed_at":"2023-05-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Surrozen Q1 net loss widens to $14.3M; cash at $61.7M; SZN-043 and SZN-1326 trials enroll","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $14.3M vs $7.9M in Q1 2022, driven by $1.2M restructuring charges and higher G&A.","Cash, equivalents and marketable securities $61.7M, down from $75.8M at Dec 31, 2022.","R&D expenses $8.1M, down from $9.4M YoY due to January 2023 restructuring reducing workforce ~25%.","SZN-043 Phase 1a enrollment ongoing in chronic liver disease; safety data expected end of 2023.","SZN-1326 Phase 1a re-initiated in Q2 2023; safety data also expected by end of 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.48,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":307210407.48949176,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":303091,"accession_number":"0000950170-23-011915","cik":1824893,"company_name":"Surrozen, Inc./DE","ticker":"SRZN","form_type":"8-K","filed_at":"2023-04-05T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Surrozen appoints Eric Bjerkholt as Class I director and audit committee member","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Eric Bjerkholt appointed to board as Class I director effective April 5, 2023.","He will serve on the audit committee.","Bjerkholt is CFO of Chinook Therapeutics; previously CFO of Aimmune, leading its $2.6B sale to Nestle.","Compensation: $35,000 annual retainer, $7,500 audit retainer, initial option grant of 40,000 shares vesting over 36 months.","Standard indemnification agreement entered with Bjerkholt."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":307210407.48949176,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":322730,"accession_number":"0000950170-23-009326","cik":1824893,"company_name":"Surrozen, Inc./DE","ticker":"SRZN","form_type":"8-K","filed_at":"2023-03-23T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Surrozen updates pipeline; cash $75.8M, net loss improves; SZN-043 and SZN-1326 timelines","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash, equivalents and marketable securities $75.8M at Dec 31, 2022, down from $123.5M; runway into H2 2024.","Collaboration revenue $12.5M from Boehringer Ingelheim deal; net loss improved to $36.0M from $54.6M in 2021.","SZN-043: Phase 1a in chronic liver disease enrolled first patient, data expected end 2023; Phase 1b in severe alcoholic hepatitis in 2024.","SZN-1326: expect to re-initiate Phase 1a in healthy volunteers mid-2023 with lower dose; Phase 1b UC data H2 2024.","Boehringer partnership for SZN-413: potential $10M milestone upon lead candidate nomination by end 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":307210407.48949176,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":322729,"accession_number":"0000950170-23-009202","cik":1824893,"company_name":"Surrozen, Inc./DE","ticker":"SRZN","form_type":"8-K","filed_at":"2023-03-22T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Surrozen reports FY2022 net loss of $36M; cash runway into H2 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for FY2022 was $36.0M vs $54.6M in FY2021; collaboration revenue $12.5M from Boehringer Ingelheim deal.","Cash, equivalents and marketable securities $75.8M as of Dec 31, 2022, down from $123.5M a year ago.","Restructuring reduces operating expenses by ~15% in 2023; cash runway extends into second half of 2024.","SZN-043 Ph1a enrolled first chronic liver disease patient, data expected end 2023; SZN-1326 Ph1a to reinitiate mid-2023.","Repurchased 5.38M shares and 1.31M warrants from Consonance for ~$2.7M; Consonance no longer holds shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":307210407.48949176,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":322728,"accession_number":"0000950170-23-000250","cik":1824893,"company_name":"Surrozen, Inc./DE","ticker":"SRZN","form_type":"8-K","filed_at":"2023-01-05T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Surrozen receives Nasdaq notice for non-compliance with $1.00 minimum bid price","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Average closing price of common stock fell below $1.00 over 30 consecutive trading days as of Jan 3, 2023.","Company has 180 days, until July 3, 2023, to regain compliance by closing at $1.00+ for 10 consecutive business days.","If not cured, Surrozen may be eligible for a second 180-day period if it meets other initial listing standards.","Notice has no immediate effect on listing; stock continues to trade on Nasdaq Capital Market.","Company will monitor bid price and evaluate options; no assurance of regaining compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":307210407.48949176,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":340778,"accession_number":"0000950170-22-026578","cik":1824893,"company_name":"Surrozen, Inc./DE","ticker":"SRZN","form_type":"8-K","filed_at":"2022-12-15T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Surrozen repurchases 5.38M shares and 1.31M warrants from Consonance for $2.7M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Repurchased 5,382,499 common shares and warrants for 1,310,496 shares from Consonance Entities on Dec. 15, 2022.","Total purchase price was approximately $2.7 million; shares returned to authorized/unissued and warrants cancelled.","Consonance Entities no longer hold any Surrozen common stock or warrants following the transaction."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":307210407.48949176,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":340777,"accession_number":"0000950170-22-025228","cik":1824893,"company_name":"Surrozen, Inc./DE","ticker":"SRZN","form_type":"8-K","filed_at":"2022-11-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Surrozen pauses SZN-1326 Phase 1 trial due to liver enzyme elevations; Q3 net loss $13.4M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Voluntarily paused SZN-1326 Phase 1 SAD trial after grade 3 ALT/AST elevations in 3 subjects; transaminases resolved spontaneously.","SZN-043 Phase 1 ongoing but with grade 1-2 transaminase elevations; re-evaluating timeline.","Entered partnership with Boehringer Ingelheim for SZN-413; upfront $12.5M, milestones up to $586.5M plus royalties.","Q3 2022 cash $78.4M (down from $92.7M in Q2); R&D expense $8.6M, net loss $13.4M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":307210407.48949176,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":340776,"accession_number":"0000950170-22-019332","cik":1824893,"company_name":"Surrozen, Inc./DE","ticker":"SRZN","form_type":"8-K","filed_at":"2022-10-06T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Surrozen enters $12.5M upfront license deal with Boehringer Ingelheim for Fzd4 bispecific antibodies","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Upfront payment of $12.5 million; eligible for up to $586.5M in development, regulatory, and commercial milestones.","Royalties on net sales range from mid-single digit to low-double digit, subject to standard reductions.","Boehringer Ingelheim leads development and commercialization of SZN-413 and other Fzd4 bispecifics for retinal diseases.","5-year exclusivity: Surrozen cannot develop Fzd4 bispecifics for eye diseases; BI restricted to eye diseases.","Collaborative research period of one year (BI may extend 6 months) after which BI selects lead and back-up candidates."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":307210407.48949176,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":357972,"accession_number":"0000950170-22-016735","cik":1824893,"company_name":"Surrozen, Inc./DE","ticker":"SRZN","form_type":"8-K","filed_at":"2022-08-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Surrozen becomes clinical-stage with Phase 1 starts for SZN-1326 and SZN-043","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Initiated Phase 1 trial for SZN-1326 (ulcerative colitis) in May 2022 and for SZN-043 (alcoholic hepatitis) in June 2022.","Presented preclinical data for SZN-413 (diabetic retinopathy) at ARVO and for other pipeline programs at Digestive Disease Week.","Q2 2022 financial results reported but specific figures (revenue, EPS, net loss) not included in provided exhibit text.","Company noted no treatment-related adverse effects in preclinical toxicology studies for both lead candidates."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.63,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":307210407.48949176,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":376656,"accession_number":"0000950170-22-011611","cik":1824893,"company_name":"Surrozen, Inc./DE","ticker":"SRZN","form_type":"8-K","filed_at":"2022-06-14T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Surrozen shareholders elect two directors, ratify Ernst & Young as auditor at 2022 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Tim Kutzkey and Anna Berkenblit as directors until the 2025 annual meeting.","Ratified Ernst & Young as independent auditor for fiscal 2022 (22,467,087 for, 1,702 against).","64% of eligible shares voted (22,468,813 of 35,125,886)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":307210407.48949176,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":376655,"accession_number":"0000950170-22-009148","cik":1824893,"company_name":"Surrozen, Inc./DE","ticker":"SRZN","form_type":"8-K","filed_at":"2022-05-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Surrozen reports Q1 2022 results; Phase 1 trials on track for Q3","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Q1 financial results announced; no specific revenue or loss figures in the press release excerpt.","On track to initiate Phase 1 trials for SZN-1326 (ulcerative colitis) and SZN-043 (alcoholic hepatitis) in Q3 2022.","Presented preclinical data for SZN-413 (retinal vascular diseases) at ARVO showing Wnt activation and vessel regrowth.","Preclinical data for lacrimal gland and lung Wnt modulation highlighted."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":307210407.48949176,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":395020,"accession_number":"0000950170-22-004485","cik":1824893,"company_name":"Surrozen, Inc./DE","ticker":"SRZN","form_type":"8-K","filed_at":"2022-03-24T23:59:59+00:00","items":["2.02","5.08","9.01"],"status":"ready","headline":"Surrozen reports full-year 2021 net loss of $47.3M; on track for Phase 1 starts in Q3 2022","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2021 net loss $47.3M vs $20.4M in 2020; R&D expenses $35.5M.","Cash and equivalents $137.8M as of Dec 31, 2021.","Phase 1 trials for SZN-1326 (ulcerative colitis) and SZN-043 (alcoholic hepatitis) expected to start Q3 2022.","Nominated SZN-413, a Fzd4 bi-specific antibody, for retinal vascular diseases including wet AMD.","2022 Annual Meeting set for June 7, 2022; record date April 11, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":307210407.48949176,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":395019,"accession_number":"0000950170-22-001988","cik":1824893,"company_name":"Surrozen, Inc./DE","ticker":"SRZN","form_type":"8-K","filed_at":"2022-02-24T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Surrozen enters $50M equity purchase agreement with Lincoln Park Capital Fund","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Up to $50M of common stock may be sold to Lincoln Park over 36 months after Commencement.","100,000 commitment shares issued at signing; $100,000 additional payment due if $30M sold.","Sales price based on market; Regular Purchases up to 30,000 shares/day at discount to market.","Lincoln Park prohibited from shorting stock; Company controls timing and amount of sales.","Registration statement for resale of shares must be filed by April 15, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":307210407.48949176,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":395018,"accession_number":"0000950170-22-000190","cik":1824893,"company_name":"Surrozen, Inc./DE","ticker":"SRZN","form_type":"8-K","filed_at":"2022-01-10T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Surrozen expects to start Phase 1 trials for SZN-1326 and SZN-043 in Q3 2022; nominates SZN-413 candidate","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Expects to initiate Phase 1 clinical trials of SZN-1326 and SZN-043 in Q3 2022.","Nominated SZN-413, a mono Fzd4 bi-specific antibody, for retinal vascular diseases including wet AMD and diabetic retinopathies.","None of the product candidates have been tested in humans or gained regulatory approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":307210407.48949176,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":413703,"accession_number":"0000950170-21-004608","cik":1824893,"company_name":"Surrozen, Inc./DE","ticker":"SRZN","form_type":"8-K","filed_at":"2021-11-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Surrozen Q3 2021 net loss $14.0M; cash $135.4M post business combination","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents and marketable securities $135.4M as of Sept 30, 2021, up from $18.9M at June 30, 2021.","Net loss of $14.0M for Q3 2021 vs $8.6M in Q3 2020; R&D expenses $10.4M (Q3 2021) vs $7.0M.","Plan to initiate Phase 1a trials for SZN-1326 (ulcerative colitis) and SZN-043 (alcoholic hepatitis) in 2022.","Pre-clinical data for both candidates presented at medical congresses; five new discovery programs initiated."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.86,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":307210407.48949176,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":432172,"accession_number":"0001193125-21-249342","cik":1824893,"company_name":"Surrozen, Inc./DE","ticker":"SRZN","form_type":"8-K","filed_at":"2021-08-17T23:59:59+00:00","items":["1.01","2.01","5.02","3.02","9.01","4.01","3.03","5.01","5.05","5.06"],"status":"ready","headline":"Surrozen completes SPAC merger; PIPE raises $120.2M, shares trade on Nasdaq under SRZN","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Business combination closed Aug 11, 2021; CHFW domesticated as Delaware corporation renamed Surrozen, Inc.","PIPE Financing of $120.2M consummated; 12.02M units at $10.00 per unit with one-third warrant.","6.75M shares redeemed for $67.5M cash; post-merger shares: 35.0M common, 3.2M IPO warrants, 4.0M PIPE warrants.","Surrozen pre-merger net loss $25.7M for H1 2021; accumulated deficit $113.7M as of June 30, 2021.","Pro forma cash increase of ~$123.1M; existing cash of $25.4M plus PIPE proceeds after transaction costs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":307210407.48949176,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":432171,"accession_number":"0001193125-21-244260","cik":1824893,"company_name":"Surrozen, Inc./DE","ticker":"SRZN","form_type":"8-K","filed_at":"2021-08-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Surrozen completes SPAC merger; Nasdaq listing under SRZN/SRZNW on Aug 12","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Business combination with Consonance-HFW Acquisition Corp. closed August 11, 2021.","Common stock and warrants start trading on Nasdaq August 12 under SRZN and SRZNW.","Transaction approved by Consonance-HFW shareholders on August 10 and Surrozen stockholders.","Existing management, led by CEO Craig Parker, to continue leading the combined company.","Surrozen focuses on Wnt pathway therapeutics for tissue repair and regeneration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":307210407.48949176,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":432170,"accession_number":"0001193125-21-242047","cik":1824893,"company_name":"Surrozen, Inc./DE","ticker":"SRZN","form_type":"8-K","filed_at":"2021-08-10T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"CHFW shareholders approve merger with Surrozen; all proposals pass with >97% support","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["BCA approved with 9,712,408 votes for, 176,605 against, 56,351 abstentions.","Domestication from Cayman Islands to Delaware and new charter/bylaws approved by special resolution.","Stock issuance to PIPE investors and Surrozen stockholders authorized (9,712,208 for).","Surrozen 2021 Equity Incentive Plan and Employee Stock Purchase Plan approved (9,712,208 for).","Adjournment proposal not voted upon as meeting proceeded without need for adjournment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":307210407.48949176,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2021-08-10T23:59:59+00:00|432170"}